Skip to main content

Basic Materials

Croda International PLC CRDA View profile

Deutsche Bank upgrades Croda as recovery gathers pace

Flat bottom of Erlenmeyer flask — Credit: Photo by Vedrana Filipović on Unsplash
Photo by Vedrana Filipović on Unsplash

Croda International has been upgraded to 'buy' from 'hold' by Deutsche Bank, which argues the shares have yet to catch up with the speciality chemicals group's recovery.

The broker lifted its price target to 4,100p from 3,300p, around 9% above Friday's closing price of 3,762p.

Analyst Virginie Boucher-Ferte said Croda's operational recovery is already underway, with stronger growth and better execution giving greater visibility over earnings.

Self-help measures are also playing a part, she added.

The Consumer Care division, which supplies ingredients for cosmetics and personal care products, is accelerating.

Deutsche Bank said Croda's targets for 2028 offer a credible path to higher margins and stronger free cash flow.

It expects double-digit growth in earnings per share, helped by a likely share buyback.

The broker described the valuation as compelling, even though its forecasts for the Life Sciences division remain conservative.

Those assumptions leave the unit earning below its potential through 2028, according to the analyst.

The shares have started to recover, but Deutsche Bank sees further upside.

Eventual normalisation in Life Sciences and breakthrough growth in Pharma, which supplies ingredients used in drug delivery, offer further potential gains, it said.

In early trading, the shares were up 1.7% at 3,824p.